Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for High-dose Therapy

NCT03422523 is registered in ClinicalTrials.gov with University Hospital Southampton NHS Foundation Trust as lead sponsor.

NCT NCT03422523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03422523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Atezolizumab With Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Who Are Not Candidates for High-dose Therapy
Lead sponsor
University Hospital Southampton NHS Foundation Trust
Phase
Phase 2
Overall status
Terminated
Start date
May 9, 2018
Completion date
November 18, 2021
Enrollment
53 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma, refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma